Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

William Baly

Internal Medicine Orangeburg, SC Medical Doctor

NPI 1831108919 CMS profile 219059

1750 Village Park Dr, Orangeburg, SC 29118

Open in the dashboard

General payments

$1,977

124 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, William Baly of Orangeburg, SC is reported in the CMS Open Payments database as having received $1,977 across 124 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 79th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $33 1
2023 General $119 7
2022 General $337 19
2021 General $658 42
2020 General $416 27
2019 General $413 28

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • William Baly
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to William Baly were reported at $33. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year William Baly Internal Medicine median Middle half National median
2019 $413 $159 $48–$570 $163
2020 $416 $119 $33–$402 $114
2021 $658 $135 $37–$521 $132
2022 $337 $141 $42–$496 $149
2023 $119 $149 $45–$519 $160
2024 $0 $154 $47–$537 $164
2025 $33 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $363 22 payments
  2. Lilly USA, LLC $245 15 payments
  3. AbbVie, Inc. $200 16 payments
  4. AstraZeneca Pharmaceuticals LP $186 13 payments
  5. Abbott Laboratories $114 6 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $108 6 payments
  7. Amarin Pharma Inc. $101 7 payments
  8. Sanofi-Aventis U.S. LLC $70 4 payments
  9. Astellas Pharma US Inc $65 4 payments
  10. Salix Pharmaceuticals, a division of Bausch Health US, LLC $60 4 payments
  11. Other $465 27 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,977 124 payments
Products named General payments · program years 2019–2025
  1. Ozempic $334 20 payments
  2. RYBELSUS $254 14 payments
  3. FARXIGA $159 11 payments
  4. MOUNJARO $121 7 payments
  5. JARDIANCE Diabetes $110 7 payments
  6. CREON $101 9 payments
  7. FreeStyle Libre 2 $95 5 payments
  8. LINZESS $86 7 payments
  9. JARDIANCE Diabetes $77 4 payments
  10. TRULICITY $75 5 payments
  11. Other $1,256 80 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 160 drugs

Part D claims

10,774

Median for Internal Medicine: 777

Drug cost

$915,989

Median for Internal Medicine: $73,373

Branded share of claims

26%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 130 $136,822
Mounjaro Tirzepatide Brand 99 $113,534
Eliquis Apixaban Brand 94 $88,846
Trulicity Dulaglutide Brand 53 $67,133
Farxiga Dapagliflozin Propanediol Brand 89 $62,108
Januvia Sitagliptin Phosphate Brand 66 $45,892
Xarelto Rivaroxaban Brand 54 $42,128
Jardiance Empagliflozin Brand 48 $38,599
Linzess Linaclotide Brand 44 $25,601
Janumet Xr Sitagliptin Phos/Metformin Hcl Brand 34 $25,208

The 10 drugs with the highest cost, of 160 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 13 billing codes

Paid by Medicare

$17,571

Of which drugs: $12,015

Medicare patients

158

Average age 76

Services billed

476

92 women, 66 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 56%
Arthritis 53%
Chronic kidney disease 23%
Ischemic heart disease 22%
Depression 20%
Cancer 16%
COPD 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 29 31 $8,944
Vaccine for influenza for injection into muscle 90653 Office 37 37 $3,027

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

124 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record